Ghaith Abu-Zeinah, MD, Weill Cornell Medicine and the New York Presbyterian Hospital, New York City, NY, highlights the drawbacks of the current risk stratification system in polycythemia vera (PV), including its non-dynamic approach and lack of personalization, which may place patients into incorrect risk groups over time. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.